HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
THURSDAY, Oct. 26, 2017 (HealthDay News) -- For patients with oropharyngeal squamous cell carcinoma (OPSCC), transoral robotic surgery (TORS) alone is associated with improved outcomes versus TORS followed by adjuvant treatment, according to a study published online Oct. 26 in JAMA Otolaryngology -- Head & Neck Surgery.
Virginie Achim, M.D., from Oregon Health and Science University in Portland, and colleagues compared functional speech, swallowing, and quality-of-life outcomes for those undergoing TORS only and those undergoing TORS and adjuvant radiotherapy (TORS+RT) or TORS and chemoradiotherapy (TORS+CRT). Data were included for 74 patients undergoing TORS for initial treatment of OPSCC and were collected at baseline, postoperatively, and at short- and long-term follow-up.
The researchers found that the response rates were 86, 88, and 86 percent postoperatively and at short- and long-term follow-up, respectively. There was a significant worsening in pain and all swallowing-related measures postoperatively in all three treatment groups. The improvement in postoperative dysphagia was significantly quicker in the TORS-only group. Weight loss differed between the TORS-only and TORS+RT groups and the TORS-only and TORS+CRT groups in a clinically meaningful way at long-term follow-up (mean differences, −16.1 [95 percent confidence interval, −29.8 to −2.4] and −14.6 [95 percent confidence interval, −29.2 to 0], respectively). The TORS-only group had significantly better scores on the Performance Status Scale-Eating in Public scale and Head and Neck Quality of Life-Eating scale than the TORS+CRT group.
"These findings support the investigation of adjuvant de-escalation therapies to reduce the long-term adverse effects of treatment," the authors write.
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at email@example.com with any questions.
Updated on May 29, 2022